profit from every ₹100 of sales.
₹0₹100
AstraZeneca Pharma India
₹6,512.20+0.50% today
-28.7% in 1 year
1-year low ₹5,704.051-year high ₹9,162.75
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹86.82 for every ₹1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What AstraZeneca Pharma India sold, what it kept, and what it did with the cash.
Sales went from ₹10.0 billion in 2023 to ₹22.8 billion in 2026, with ₹1.88 billion of profit last year.
SalesProfit
AstraZeneca Pharma India vs. similar companies
AstraZeneca Pharma India grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| AstraZeneca Pharma India | 86.8× · Very expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads AstraZeneca Pharma India's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 10,030 | 12,955 | 17,163 | 22,756 | |
| 5,777 | 6,223 | 7,533 | 8,950 | |
| 1,489 | 1,714 | 2,140 | 2,335 | |
| 1,510 | 2,357 | 1,978 | 2,853 | |
| 993 | 1,615 | 1,157 | 1,875 | |
| 39.70 | 64.60 | 46.30 | 75.01 | |
| 57.6% | 48.0% | 43.9% | 39.3% | |
| 14.8% | 13.2% | 12.5% | 10.3% | |
| 9.9% | 12.5% | 6.7% | 8.2% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 9,849 | 10,780 | 15,181 | 19,891 |
| Cash | 5,003 | 5,056 | 5,361 | 4,477 |
| Total debt | 72 | 46 | 357 | 1,107 |
| Total liabilities | 3,962 | 3,661 | 7,478 | 11,163 |
| 5,887 | 7,119 | 7,704 | 8,728 | |
| 25 | 25 | 25 | 25 | |
| 17.9% | 24.3% | 15.5% | 20.6% | |
| 16.9% | 22.7% | 15.0% | 21.5% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 583 | 279 | 654 | -151 | |
| 85 | 108 | 18 | 36 | |
| 498 | 171 | 636 | -188 | |
| Dividends paid | 200 | 400 | 600 | 800 |
| – | – | – | – | |
| 24 | 27 | 51 | 11 |
Valuation
- 86.8×
- –
- 3.67
- –
- 7.2×
- –
- 55.9×
- -0.1%
- 1.2%
- 0.5%
Profitability
- 39.3%
- 10.3%
- 8.2%
- –
- 19.6%
- 18.6%
- –
- –
- –
- –
Growth
- +31.4%
- +23.6%
- –
- –
- −0.0%
Financial health
- -1.2×
- 0.13
- –
- 57.2×
- 1.77
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 9%of 948
Top 47%of 871
Bottom 11%of 560
Top 19%of 868
Bottom 40%of 985
0.5%of the share price, paid each year
On $1,000 invested$5a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
42.7% of its profit
Room to growStretchedMore than it earnsNews
Notable healthcare headlines for the week: Eli Lilly, Merck, and AstraZeneca in focusSeeking Alpha · Nov 1, 2026AstraZeneca Q3 profit beats estimates as cancer drug sales drive growthSeeking Alpha · Oct 30, 2026AstraZeneca PLC Non-GAAP EPS of $2.79, revenue of $16.21B beats by $210M; reaffirms FY2026 outlookSeeking Alpha · Oct 30, 2026AstraZeneca is said to be considering cancer vaccine developmentSeeking Alpha · Oct 27, 2026Summit Therapeutics rises after AstraZeneca commits $2B investmentSeeking Alpha · Sep 28, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
54No pass
Philip Fisher
53No pass
Peter Lynch
57No pass
Joel Greenblatt
18No pass
Charlie Munger
53No pass
Terry Smith
42No pass
Questions about AstraZeneca Pharma India
Is AstraZeneca Pharma India a good stock to buy?
A solid business, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AstraZeneca Pharma India AI analysis
What does AstraZeneca Pharma India do?
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Bengaluru, India, with 600 employees.
Does AstraZeneca Pharma India pay a dividend?
Yes. At today's price the dividend is 0.5% a year, about 43% of its yearly profit. In 2026 it paid out ₹800 million in dividends.
Is AstraZeneca Pharma India stock halal?
Yes. AstraZeneca Pharma India passes our halal screen: its business is permitted and its debt is 0.7% of its market value, under the 30% limit. How we check
How has AstraZeneca Pharma India stock done over the past year?
Down 28.7% over the past twelve months, to ₹6,512.20. It traded between ₹5,704.05 and ₹9,162.75 and is 28.9% below its high.
Who are AstraZeneca Pharma India's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with AstraZeneca Pharma India's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.